Market capitalization | $2.95m |
Enterprise Value | $14.90m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.58 |
P/S ratio (TTM) P/S ratio | 0.51 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 390.03% |
Revenue (TTM) Revenue | $5.77m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast INVO Bioscience Inc:
1 Analyst has issued a forecast INVO Bioscience Inc:
Jun '24 |
+/-
%
|
||
Revenue | 5.77 5.77 |
389%
389%
|
|
Gross Profit | 1.97 1.97 |
328%
328%
|
|
EBITDA | -4.62 -4.62 |
51%
51%
|
EBIT (Operating Income) EBIT | -5.24 -5.24 |
45%
45%
|
Net Profit | -7.08 -7.08 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
INVO BioScience, Inc. focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Medford, MA.
Head office | United States |
CEO | Steven Shum |
Employees | 30 |
Founded | 2007 |
Website | www.invobioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.